Parkman Healthcare Partners LLC Has $4.41 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Parkman Healthcare Partners LLC increased its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 26.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 347,541 shares of the company's stock after acquiring an additional 73,076 shares during the period. Parkman Healthcare Partners LLC owned approximately 1.48% of UroGen Pharma worth $4,414,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of URGN. Great Point Partners LLC grew its stake in UroGen Pharma by 10.9% in the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company's stock valued at $48,767,000 after acquiring an additional 285,714 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company's stock worth $41,099,000 after purchasing an additional 1,337,257 shares in the last quarter. Cowen AND Company LLC raised its position in shares of UroGen Pharma by 29.1% during the 2nd quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company's stock worth $35,229,000 after purchasing an additional 472,893 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in UroGen Pharma by 1.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company's stock valued at $17,032,000 after buying an additional 21,072 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of UroGen Pharma by 2,672.0% in the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company's stock valued at $19,480,000 after acquiring an additional 1,119,019 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN traded up $0.12 during trading hours on Wednesday, hitting $12.46. The stock had a trading volume of 293,018 shares, compared to its average volume of 496,649. UroGen Pharma Ltd. has a 1-year low of $10.60 and a 1-year high of $20.70. The stock's fifty day simple moving average is $12.31 and its 200 day simple moving average is $13.99. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a market capitalization of $292.24 million, a price-to-earnings ratio of -3.98 and a beta of 1.06.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same period in the prior year, the firm earned ($0.68) EPS. Sell-side analysts anticipate that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a "strong-buy" rating in a research note on Monday, October 14th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Oppenheimer restated an "outperform" rating and set a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, Guggenheim started coverage on UroGen Pharma in a research report on Thursday, August 22nd. They set a "buy" rating and a $40.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, UroGen Pharma currently has an average rating of "Buy" and an average price target of $48.38.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.